Group 5 Type of group

2 trials

Sponsors

SCHERING PLOUGH RESEARCH INSTITUTE,, NOVARTIS BIOSCIENSES PERU S.A.,

Unknown Phase

A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting

Active, not recruitingPER-057-06

SCHERING PLOUGH RESEARCH INSTITUTE,

Target: 39Updated: 2023-09-04

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

Active, not recruitingPER-057-09

NOVARTIS BIOSCIENSES PERU S.A.,

Target: 36Updated: 2023-09-04